LENZ Therapeutics and Laboratoires Théa partner to commercialize LNZ100 for presbyopia in Canada

(Image Credit: AdobeStock/Rob)

LENZ Therapeutics and Laboratoires Théa have announced a license and commercialization agreement for Théa to register and commercialize LNZ100 for the treatment of presbyopia in Canada.¹

In October 2024, LENZ announced that the US Food and Drug Administration (FDA) accepted the new drug application for LNZ100 for the treatment of patients with presbyopia.

Later, in March 2025, LENZ Therapeutics announced that the FDA had assigned a Prescription Drug User Fee Act (PDUFA) target action date of August 8, 2025, for LNZ100. In the US, commercial launch activities will commence immediately following a potential FDA approval.²

Under the terms of the agreement between LENZ and Théa, LENZ will be eligible to receive over $70 million in up-front, regulatory, and commercial milestone payments, as well as tiered, double-digit royalties on net sales. Théa will have exclusive development, manufacturing, registration, and commercialization rights for LNZ100 for the treatment of patients with presbyopia in Canada.

Eef Schimmelpennink, president and CEO of LENZ Therapeutics, commented on the partnership in a press release from the company, saying, “Théa is a leading company in eye care in key markets around the world and was a natural choice for LENZ when looking for a highly capable commercial partner in Canada. With its strong position in commercializing eye drops, Théa is uniquely positioned to bring the benefits of LNZ100 to patients in this key market. This agreement represents our third commercialization partnership outside the United States for LNZ100, as we continue to be focused on maximizing patient access to this important therapy worldwide.”

Other partnerships Schimmelpennink mentioned include one with Lotus Pharmaceutical for the exclusive license and commercialization agreement for Lotus to commercialize LNZ100 for the treatment of patients with presbyopia in the Republic of Korea and certain countries in Southeast Asia.³

At the time of writing, LNZ100 has not been approved for use in Canada.

References

1. LENZ Therapeutics and Laboratoires Théa announce exclusive license and commercialization agreement for LNZ100 in Canada. News release. LENZ Therapeutics, Inc. July 7, 2025. Accessed July 7, 2025. https://www.globenewswire.com/news-release/2025/07/07/3110985/0/en/LENZ-Therapeutics-and-Laboratoires-Th%C3%A9a-Announce-Exclusive-License-and-Commercialization-Agreement-for-LNZ100-in-Canada.html

2. LENZ Therapeutics reports fourth quarter and full year 2024 financial results and recent corporate highlights. Press release. LENZ Therapeutics, Inc. March 19, 2025. Accessed July 7, 2025. https://ir.lenz-tx.com/news-events/press-releases/detail/30/lenz-therapeutics-reports-fourth-quarter-and-full-year-2024-financial-results-and-recent-corporate-highlights

3. LENZ Therapeutics and Lotus Pharmaceutical announce exclusive license and commercialization agreement for LNZ100 in the Republic of Korea and Southeast Asia. News release. LENZ Therapeutics, Inc. May 9, 2025. Accessed July 7, 2025. https://www.theglobeandmail.com/investing/markets/stocks/LENZ-Q/pressreleases/32315125/lenz-therapeutics-and-lotus-pharmaceutical-announce-exclusive-license-and-commercialization-agreement-for-lnz100-in-the-republic-of-korea-and-southeast-asia/